Suzanne Hendrix, PhD, Pentara Corporation, Salt Lake City, UT, advocates for the shift in evaluating degenerative diseases by ‘time saved’ as a measure of clinical meaningfulness. With the recent rise of disease-modifying therapies (DMTs) in Phase III trials, many questions have been raised about how to interpret changes on clinical scales and the relevance of these metrics to individual patients. Commonly used scales, such as CDR-SOB or ADAS-Cog, do not allow for suitable contextualization of the slow progression in the early phases of dementia. For example, slowing decline by 0.5 points may be meaningful in early stage disease, where typical decline over 18 months is only 1 point. In later disease, 0.5 points slowing would be less clinically meaningful. Expressing the difference between treatment and placebo use as how much time has been saved is more easily and consistently interpreted. This interview took place at the AD/PD™ 2023 congress in Gothenburg, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
